60 Degrees Pharma To Present Review Of Safety, Efficacy Data Of 8-Aminoquinolines For Malaria And Babesiosis Treatment At ILADS Annual Scientific Meeting In Boston
Portfolio Pulse from Happy Mohamed
60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) will present a scientific poster on the long-term safety data of tafenoquine for malaria prevention at the ILADS 2023 annual scientific meeting. The company will also review the use of 8-aminoquinolines in treating malaria and babesiosis. Tafenoquine is approved for malaria prophylaxis in the US under the product name ARAKODA®. However, it has not been proven effective for treatment or prevention of babesiosis and is not FDA approved for such indications.
October 19, 2023 | 12:42 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
60 Degrees Pharmaceuticals will present data on tafenoquine, a drug approved for malaria prophylaxis, and discuss its potential use for babesiosis. However, the drug is not yet FDA approved for this indication.
The presentation of safety data and potential use of tafenoquine for babesiosis could generate interest in 60 Degrees Pharmaceuticals. However, as the drug is not yet FDA approved for this indication, it's uncertain how this will impact the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100